Working… Menu
Trial record 1 of 1 for:    03088878
Previous Study | Return to List | Next Study

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03088878
Recruitment Status : Recruiting
First Posted : March 23, 2017
Last Update Posted : July 8, 2020
California Institute for Regenerative Medicine (CIRM)
Oncternal Therapeutics, Inc
Information provided by (Responsible Party):
Michael Choi, University of California, San Diego